During the emergence of the pandemic, Croda has actively reached out to research groups around the world, offering free of charge material and expertise.
Croda International has a strong purpose to use smart science to improve lives and its Health Care division, specialists in vaccine adjuvant technologies, is demonstrating that by proactively partnering with academia to provide valued material for global vaccine developments around COVID-19.
Their saponin-based and aluminium-based vaccine adjuvants are actively being used and are now part of prototype vaccines.
With more than 80 years of experience in this area, the team are well placed to support the delivery of a safe and effective vaccine for the rapidly spreading disease.
Peter Tygesen, Managing Director of Croda’s vaccine adjuvant business, said: “The health and wellbeing of our employees is our priority during the outbreak of Covid-19. We are managing to keep our sites working at this time to provide crucial vaccine adjuvants for pharmaceuticals, including those needed to help in the development of a vaccination for COVID-19."
"We are proud of the role our industry-leading adjuvants can play here and are supporting research groups however we can.”